Fitch Solutions Strengthens Counterparty Risk Solution with ‘AI’ Powered News, Expanded Macroeconomic Data and New Global Bank Rankings
Fitch Solutions today announced a number of powerful enhancements to its Counterparty Risk Solutions, each designed to help risk professionals make faster and more insightful decisions. The Counterparty Risk Solution now includes a curated news monitoring service, Country Risk Data from BMI Research, and Bank Rankings – all delivered through the Fitch Connect platform.
Fitch Connect News: This innovative offering uses machine learning and text mining technologies to gauge news sentiment on user-defined portfolio of banks, curated from thousands of global sources. This unique service applies a ‘negativity algorithm’ against entity and portfolio content, learning to deliver increasingly relevant content based on user behavior and delivered within his or her credit risk workflow.
Country Risk Data: This qualitative view of BMI Research’s macroeconomic data, forecasts and risk indices features macroeconomic and political risk analysis for 163 countries globally, and covering 99.9% of global GDP. BMI’s macroeconomic and political risk content is combined with Fitch’s proprietary content and relevant financial data.
Bank Rankings: Leveraging its extensive Fundamental Financial Data, Fitch Solutions has developed a Bank Ranking methodology to offer insight into banks’ positioning on a global and country basis. Bank Rankings provide a clear indication of a bank’s relative standing compared to peers, both current and historic. Bank Rankings are available based on Total Assets, Risk Weighted Assets, Tier 1 Capital and Operating Profit.
Brian Filanowski, Global Head of Product, Fitch Solutions, commented: “By listening to our users, we continue to offer differentiated solutions targeted at helping relieve some of the pain-points in their workflow. The release of the curated news monitoring service is a great example of a differentiated solution. Our innovative offering saves our users time sifting through various news websites and allows them to spend more time on managing their exposures and mitigating risks.”
Fitch Solutions is a leading provider of solutions for counterparty credit risk professionals. Fitch’s Fundamental Financial Data has the largest coverage of bank fundamentals in the market, economic data on sovereigns, including 3-year forecast data, as well as financials on insurers and corporates. The Counterparty Risk Solution also includes access to credit ratings and research from Fitch Ratings, as well as Financial Implied Ratings and other analytics that provide insights into local market dynamics and what is behind the numbers. The suite of products and services that comprise the Counterparty Risk Solution is available through a number of delivery channels, including desktop and enterprise applications.
“Over the last ten years, the financial services sector has been undergoing a transformation that involved the introduction of many new systems and processes to comply with financial regulation,” said Mr. Filanowski. “Our goal is to help counterparty risk managers by integrating relevant content from various sources into one tailored solution that helps drive fast and insightful decisions.”
Fitch Solutions is a world-leading provider of credit intelligence and the primary distributor of Fitch Ratings content. Today, 90% of the world’s leading banks and financial institutions, as well as multinational companies, government agencies, and consulting firms based in more than 118 countries depend on Fitch content to inform their business decisions.
BMI Research is a leading provider of macroeconomic and industry research, and analytics. For over 30 years, BMI has produced quality analysis and forecasts on macroeconomics, political risk, capital markets, and 22 industry sectors.
Together, Fitch Solutions and BMI Research comprise the information services business of Fitch Group, a leading provider of essential financial information and services to the global financial markets. Fitch Group is majority-owned by Hearst.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i